This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Afatinib* is an irreversible ErbB Family blocker that selectively, potently and irreversibly binds to and blocks EGFR (ErbB1), HER2 (ErbB2) and ErbB4.1,2 This page details afatinib’s licensing and MoA.
Afatinib (GIOTRIF®) is an irreversible tyrosine kinase inhibitor (TKI) that is approved as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. In most countries it is restricted to EGFR tyrosine kinase inhibitor (TKI)-naïve patients.
Afatinib is also approved in some countries including the US and the EU for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.3
Afatinib’s Mechanism Of Action
Afatinib selectively, potently and irreversibly binds to and blocks EGFR (ErbB1), HER2 (ErbB2) and ErbB4. In doing so, afatinib blocks downstream signalling from all homo- and heterodimers formed by ErbB Family members.1,2 Its ability to block all ErbB Family members differentiates afatinib from first- and third-generation TKIs, and its irreversible binding differentiates from first-generation, reversible EGFR TKIs. Afatinib contains an electrophilic group that is able to covalently bind to conserved cysteine residues within the catalytic domains of EGFR (Cys797), HER2 (Cys805), and ErbB4 (Cys803).4 Accordingly, in preclinical studies, afatinib has shown greater inhibitory activity against activating EGFR mutations than reversible EGFR TKIs.2,5
Afatinib, an irreversible ErbB Family blocker
EGF, epithelial growth factor; EGFR, epithelial growth factor receptor.
Watch afatinib's mechanism of action
Watch afatinib’s mechanism of action
The ErbB Family Of Receptors
The ErbB Family of receptors has four members. HER2 (ErbB2) lacks a ligand-binding domain, and is the preferred dimerisation partner for the other receptors.
Ligand binding and dimerisation of these receptors activate cell proliferation and survival pathways; this occurs via a number of different homo- and heterodimers:6,7
EGFR, epithelial growth factor receptor.
Genetic alterations to members of the ErbB Family, such as mutations or overexpression, have been reported in NSCLC, including in squamous cell carcinoma.8-20 Mutations in ErbB receptor tyrosine kinases can lead to overexpression or overactivation, which results in uncontrolled cell proliferation, inhibition of apoptosis, and promotion of tumour growth and spread.1,4,7,21
Reid A, et al. Eur J Cancer 2007;43(3):481-9.
Li D, et al. Oncogene 2008;27(34):4702-11.
Afatinib (GIOTRIF®) summary of product characteristics - May 2016. Accessed: July 2017.
Solca F, et al. J Pharmacol Exp Ther 2012;343(2):342-50.
Cross DA, et al. Cancer Discov 2014;4(9):1046-61.
Yarden Y, et al. Nat Rev Cancer 2012;12(8):553-63.
Hynes NE, et al. Nat Rev Cancer 2005;5(5):341-54.
Cappuzzo F, et al. J Natl Cancer Inst 2005;97(9):643-55.
Hirsch FR, et al. J Clin Oncol 2003;21(20):3798-807.
Dacic S, et al. Am J Clin Pathol 2006;125(6):860-5.
Lopez-Malpartida AV, et al. Lung Cancer 2009;65(1):25-33.
Lee HJ, et al. Lung Cancer 2010;68(3):375-82.
Gately K, et al. Clin Lung Cancer 2014;15(1):58-66.
Hirsch FR. Oncogene 2009;28 (Suppl. 1):S1-3.
Hirsch FR, et al. Oncogene 2009;28 (Suppl 1.):S32-7.
D'Arcangelo M, et al. Future Oncol 2013;9(5):699-711.
Ji H, et al. Proc Natl Acad Sci USA 2006;103(20):7817-22.
Stephens P, et al. Nature 2004;431(7008):525-6.
Yi ES, et al. Mod Pathol 1997;10(2):142-8.
Kan Z, et al. Nature 2010;466(7308):869-73.
Gazdar AF. Cancer Metastasis Rev 2010;29(1):37-48.
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue